Animal tumor models for PET in drug development

被引：0
|
作者：
Jun Toyohara
Kiichi Ishiwata
机构：
[1] Tokyo Metropolitan Institute of Gerontology,Positron Medical Center
来源：
Annals of Nuclear Medicine | 2011年 / 25卷
关键词：
Animal tumor models; Positron emission tomography; Drug development; Anticancer agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Positron emission tomography (PET) is being increasingly applied to animal tumor models due to the need for proof-of-concept testing and preclinical efficacy studies of anticancer agents. Regardless of the nature of an experiment, investigators should carefully select a suitable animal tumor model as part of the experimental design. This review introduces sources of information and the guiding principles regarding applicability of various animal tumor models for PET in anticancer agent development especially for small animals.
引用
收藏
页码：717 / 731
页数：14
相关论文
共 50 条
  • [41] The development of Wilms tumor: From WT1 and microRNA to animal models
    Tian, Fang
    Yourek, Gregory
    Shi, Xiaolei
    Yang, Yili
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1846 (01): : 180 - 187
  • [42] Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease
    Riekkinen, P
    Schmidt, BH
    van der Staay, FJ
    ANNALS OF MEDICINE, 1998, 30 (06) : 566 - 576
  • [43] Genetically modified animal models of negative symptoms: future challenges for drug development
    O'Tuathaigh, C.
    EUROPEAN PSYCHIATRY, 2019, 56 : S621 - S621
  • [44] Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development
    Hu, Jianming
    Lin, You-Yu
    Chen, Pei-Jer
    Watashi, Koichi
    Wakita, Takaji
    GASTROENTEROLOGY, 2019, 156 (02) : 338 - 354
  • [45] Animal models of chemotherapy-induced cognitive decline in preclinical drug development
    Jeena John
    Manas Kinra
    Jayesh Mudgal
    G. L. Viswanatha
    K. Nandakumar
    Psychopharmacology, 2021, 238 : 3025 - 3053
  • [46] Spontaneous and genetically engineered animal models: use in preclinical cancer drug development
    Hansen, K
    Khanna, C
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) : 858 - 880
  • [47] ANIMAL MODELS AND AMPHETAMINE ISOMERS IN ATTENTION-DEFICIT/ HYPERACTIVITY DRUG DEVELOPMENT
    Glaser, Paul E. A.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S337 - S338
  • [48] Better lab animal models for translational neuroscience research and CNS drug development
    Meshalkina, Darya A.
    Song, Cai
    Kalueff, Allan V.
    LAB ANIMAL, 2017, 46 (04) : 91 - +
  • [49] A standardised framework to identify optimal animal models for efficacy assessment in drug development
    Ferreira, Guilherme S.
    Veening-Griffioen, Desiree H.
    Boon, Wouter P. C.
    Moors, Ellen H. M.
    Gispen-de Wied, Christine C.
    Schellekens, Huub
    van Meer, Peter J. K.
    PLOS ONE, 2019, 14 (06):
  • [50] CURRENT CONCEPTS AND ANIMAL-MODELS OF SUDDEN CARDIAC DEATH FOR DRUG DEVELOPMENT
    CHAN, PS
    CERVONI, P
    DRUG DEVELOPMENT RESEARCH, 1990, 19 (02) : 199 - 207
12345